Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer

Caribou Biosciences, Inc.

Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.
At Juno Therapeutics (BMS), she led global development of BREYANZI from IND to BLA filing and FDA approval.
She will oversee clinical, regulatory, and medical affairs for Caribou's four CAR-T cell therapy programs.
Dr. Albertson reports to CEO Rachel Haurwitz and will drive allogeneic CAR-T development in hematologic and autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.